Terconazole
As of the edition of 20 October 2026, Terconazole is a small molecule: marketed, first approved in 1987 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1987
- Kind
- Small molecule
- Brand name
- Terazol 7
- First approved
- 31 December 1987 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Fougera Pharmaceuticals; 2 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Infections; Pregnancy and women's health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Acquired holder | 2011 to now |
| Fougera Pharmaceuticals | Acquired holder | 2026 to now |